The Team

Board of Directors

Keith Try Ung

Keith Try Ung

CEO / President / CTO / Co-founder

Keith has more than 20 years in drug delivery companies working for Inhale/Nektar Therapeutics and Novartis Corp. Keith received his PhD from the University of Sydney, Australia in pharmaceutical sciences and BSc in Electrical Engineering from Washington State University. He is author and co-author for number of publications and co-inventor of several patents on dry powder inhalers and improved drug delivery to bypass deposition in the extra-thoracic region and maximize total lung dose.

John Patton

John Patton

Executive Chairman / CSO / Co-founder

John is an entrepreneur who has founded or cofounded 4 inhalation delivery companies. He cofounded iPharma in 2016 and is the Executive Chairman. He previously founded Dance Biopharm (inhaled insulin) in 2009 (now Aerami Therapeutics) and served as CEO for 9+ years, and cofounded InCarda Therapeutics (inhaled medicines for the heart) in 2010 and Inhale/Nektar Therapeutics in 1990 (NKTR mkt cap $3.83B) and was the founding investor of Halozyme (HALO, mkt cap $2.76B). At Nektar, John was a key driver for the company’s business deals, including the Shearwater and Aerogen acquisitions, and participated in financings totaling >$700M. Prior to Inhale, John led the drug delivery group at Genentech from 1985-1990. John has a Ph.D. in Biology from UCSD and held post doctoral positions at the Univ of Lund, Sweden and Harvard Medical School.

John Pritchard

John Pritchard

Director

John is a physicist and experienced aerosol scientist who has led teams at GlaxoSmithKline, AstraZeneca, 3M Drug Delivery Systems and Philips Respironics. John’s fingerprints are on a significant number of inhaled products – Advair, Flovent, Symbicort, Dulera, Optichamber Diamond and Aeroneb Go to name just a few. He was a member of the UN science team that brought an end to CFCs, he contributed to the development of oropharyngeal models as a part of the GSK-AstraZeneca-Novartis Consortium, and has been an early advocate of digital health and smart devices to improve patient adherence. John was a Founding Member and President of The Aerosol Society and co-founder of the Drug Delivery to the Lungs conference in Great Britain. John was the 2018 recipient of the Charles G. Thiel Award from Virginia Commonwealth University for outstanding research and discovery in respiratory drug delivery.

Samantha Miller

Samantha Miller

Director

Samantha has >25 years of experience in the biopharma industry in progressively more senior roles. She has held strategic and operational senior management positions with a variety of private and public companies. Currently Samantha has dual roles in both an OTC women’s health company, Cadence Health, and a clinical stage company treating cardiovascular conditions by the inhalation route, InCarda Therapeutics. She is chief operating officer and co-founder for Cadence and chief business officer for InCarda, as well as serving on the board of several young companies. Prior to InCarda and Cadence, Samantha was chief business officer for Dance Biopharm, and led corporate and business development for other pharma companies, including Theravance, Inhale/Nektar, and Onyx. She began her pharmaceutical industry training with Procter & Gamble Pharmaceuticals as a marketing manager. Ms. Miller received her MSc in microbiology & immunology from the University of Rochester School of Medicine, and MBA from the University of Rochester. She also holds a B.S. in biochemistry from the University of California at San Diego.

Management Team

John Patton, PhD

John Patton, PhD

Executive Chairman / CSO / Co-founder

John is an entrepreneur who has founded or cofounded 4 inhalation delivery companies. He cofounded iPharma in 2016 and is the Executive Chairman. He previously founded Dance Biopharm (inhaled insulin) in 2009 (now Aerami Therapeutics) and served as CEO for 9+ years, and cofounded InCarda Therapeutics (inhaled medicines for the heart) in 2010 and Inhale/Nektar Therapeutics in 1990 (NKTR mkt cap $3.83B) and was the founding investor of Halozyme (HALO, mkt cap $2.76B). At Nektar, John was a key driver for the company’s business deals, including the Shearwater and Aerogen acquisitions, and participated in financings totaling >$700M. Prior to Inhale, John led the drug delivery group at Genentech from 1985-1990. John has a Ph.D. in Biology from UCSD and held post-doctoral positions at the Univ of Lund, Sweden and Harvard Medical School.

Keith Try Ung, PhD

Keith Try Ung, PhD

CEO / President / CTO / Co-founder

Keith has more than 20 years in drug delivery companies working for Inhale/Nektar Therapeutics and Novartis Corp. Keith received his PhD from the University of Sydney, Australia in pharmaceutical sciences and BSc in Electrical Engineering from Washington State University. He is author and co-author for number of publications and co-inventor of several patents on dry powder inhalers and improved drug delivery to bypass deposition in the extra-thoracic region and maximize total lung dose.

Mei-Chang Kuo, PhD

Mei-Chang Kuo, PhD

Head of Drug Development / Co-founder

With a long track record in pharmaceutical R&D, Mei-Chang Kuo has seen several new and life-cycle-management products through different phases of research and development at a several start-up and mid-size life science companies. From 1994 to 2008 at Inhale/Nektar, Dr. Kuo formulated dry powder insulin for Exubera® and was responsible for the second and third generation of insulin formulation development. As a SVP at Dance Biopharm, Kuo formulated ultra-stable liquid inhaled insulin formulations and led the API management/Drug Product manufacturing. From 1987 to 1994 as Director of Peptide Chemistry at ImmuLogic Pharm, Kuo led the development of the ALLERVAX® drug product programs and CMC drafting in the IND submissions.  From 1984 to 1987, Kuo was group leader at Polaroid/PB Diagnostic. Kuo earned a Ph.D. in Biochemistry from the University of Wisconsin, Madison, and completed an Arthritis Postdoctoral Fellowship at National Institute of Health (NIH). He is fluent in Mandarin, Cantonese and English.

Truc Le

Truc Le

Chief Compliance Officer

From 2011 to March 2020, Mr. Le was the Chief Technical Operations Officer for Aerami Therapeutics (formerly Dance Biopharm) - a leader in aqueous respiratory therapy delivery with Drug and Device combination products. As CTO at Dance, he built the Quality Systems, Manufacturing and Supply Chain, oversaw IT and Pharmaceutics. From May 2009 to July 2011, Mr. Le was the Chief Operating Officer for Avid Bio services, Inc., a leading CRO that specializes in clinical trials and commercial distribution of monoclonal antibodies and recombinant proteins. From 2007 to 2009, Mr. Le served as the SVP of Quality for Prima BioMed, a cell therapy company, and as a consultant for several drug/device companies. From 2002 to 2007, Mr. Le was SVP of Operations and Quality for Nektar Therapeutics, a biopharmaceutical company, where he led the commercial formulation and device manufacturing for Exubera. From 1981 to 1999, Truc was Worldwide Vice-President of Regulatory Compliance and Quality Systems for a division of J&J. Mr. Le has a B.S. in mechanical engineering, an M.B.A. in Management, and completed numerous executive leaderships training programs, including Duke University’s World Class Manufacturing Program and the Executive Management Program at Harvard University. Mr. Le is a certified QSR trainer at AAMI/FDA.

Strategic Advisors

Nani Kadrichu

Nani Kadrichu

Strategic Advisor

Nani is a pharmaceutical drug/device development professional with over 20 years as a recognized expert in the aerosol science field. She is currently owner and principal of Inspired Pulmonary Solutions LLC, providing pulmonary drug delivery consulting services ranging from nonclinical evaluation through commercial readiness. Previously, Nani held positions of increasing responsibility within Inhale Therapeutic Systems, Nektar Therapeutics, and Novartis Pharmaceuticals, during which time she participated in development of several small molecules and biologics (including inhaled insulin) for pulmonary administration and developed / invented numerous complex pulmonary delivery platforms and novel aerosol characterization methods. Nani holds a B.S. in Chemistry, M.S. in Engineering from West Virginia University and a Ph.D. in Aerosol Science (minor in Chemical Engineering) from University of California at Los Angeles. Nani authors / co-authors numerous publications.

Hak-Kim Chan

Hak-Kim Chan

Strategic Advisor

Hak-Kim Chan, Professor in Pharmaceutics, is leading the Advanced Drug Delivery Group at the Sydney Pharmacy School, University of Sydney, Australia. He previously worked at Genentech as a scientist developing inhalable therapeutic proteins such as Pulmozyme. His research focuses on inhalation drug delivery, ranging from aerosol formulation and inhaler device to scintigraphic imaging of lung deposition and clinical outcome. He played a pivotal role in the product development of Pharmaxis’ Aridol and Bronchitol (inhaled mannitol for bronchoprovocation and mucus clearance). His research on pulmonary drug delivery has led to >400 scientific publications (with >14,500 citations) and seven patents. He is an executive editor of Advanced Drug Delivery Reviews, a Fellow of the American Association of Pharmaceutical Scientists and Fellow of Royal Australian Chemical Institute. He served as Vice President of the Asian Federation for Pharmaceutical Sciences.

Christopher A. Rhodes

Christopher A. Rhodes

Strategic Advisor

Dr. Chris Rhodes is CEO and founder of Drug Delivery Experts, a contract services product development CDMO specializing in solution through complex injectables and small molecules through biologics with capabilities from formulation through clinical supply manufacturing, QC release, and stability. Dr. Rhodes is a pharmaceutical scientist with over 25 years of experience in product development of complex formulations and delivery systems including long-acting injectable, pulmonary, nasal, transdermal, and oral formulations for peptides, proteins, antibodies, oligonucleotides, and small molecules. He played a key role in the development of the commercial products Byetta, Lusedra, Bydureon, Myalept, and Afrezza, was an R&D leader at Amydis Diagnostics, SKS Ocular, Amylin, Guilford, and Mannkind, and was drug development team leader for a propofol prodrug, an NCE for peripheral neuropathy, and led translational research on delivery systems for exenatide, including nasal, pulmonary, oral, and transdermal microporation technologies. He is a founder of Sensulin, CASS Pharmaceuticals, and Baywind Bioventures, companies developing drug delivery enabled pharmaceutical assets. He has a PhD in chemistry (UCLA), a BS in chemistry (NYU), and was a Post Doc at Yale.

Ralph Niven

Ralph Niven

Strategic Advisor

Dr. Niven has worked in the biopharmaceutical and medical device fields >25 years and has strong familiarity with early stage companies and in developing drugs and technologies from bench to clinic. From 2012-17, Dr. Niven was responsible for the technical development of several inhalation programs at the Novartis, CA facility, prior to this, he served as CTO of APT Pharmaceuticals which completed a Phase III study of inhaled cyclosporine for lung transplant rejection. He served as SVP of Preclinical Development for Discovery Laboratories, Inc., and ran the company’s California R&D facility focusing on aerosolized synthetic lung surfactant. He also played key roles at Megabios, Inc., developing non-viral gene therapies,  Advanced Inhalation Research (Alkermes), facilitating the development of dry-powder “porous” particles for inhalation and 5 years at Amgen developing biomolecules for lung delivery. He has published ~60 research articles and book chapters and is an inventor or co-inventor of numerous patents. Ralph has a Ph.D. in Pharmaceutical Sciences (University of Kentucky 1988), completed postdocs  at Harvard School of Public Health and University of Florida, and has an MBA in Healthcare (George Washington University). He has consulted widely to biopharmaceutical companies, and served on multiple Advisory Boards including the International Society for Aerosols in Medicine and Controlled Release Society.